$NXTS

Nexentis Technologies Inc.

Nexentis Technologies operates through its wholly owned Israeli subsidiary MitoCareX Bio and a joint venture in solar energy. MitoCareX is a drug discovery company developing potential therapies for cancer and inflammatory metabolic diseases by targeting mitochondrial carrier proteins. Its work focuses on Non-Small Cell Lung Cancer and pancreatic cancer, and includes the MITOLINE™ algorithm, computational chemistry tools, in vitro screening platforms and small-molecule drug candidates. MitoCareX may generate income through partnerships, platform licensing, milestone payments and royalties on approved therapies. Nexentis also has an interest in Solterra Renewable Energy, which develops solar photovoltaic projects in Italy, Poland and Germany. Solterra’s strategy includes selling projects at different stages of development. Nexentis is headquartered in New York, NY.

0
3
0

No SEC Form 4 filings for $NXTS in the last 30 days.

See all $NXTS insider activity →

Nexentis 3Q 2026: EPS ($0.29) — 10-Q Summary

Nexentis reported a net gain of $5.0 million, up from $429,000 a year earlier, driven by higher financing income. The company had no revenue from biotech or renewable energy projects. Financing income rose $6.9 million, while R&D expenses were $288,000. MitoCareX completed an initial screening stage under its Boltz initiative.

Nexentis Technologies Inc. (NXTS): Unregistered Sales of Equity Securities

Nexentis Technologies Inc. (NXTS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02. Unregistered Sales of Equity Securities. On November 9, 2026, Nexentis Technologies Inc. (the “Company”) issued 72,000 shares of common stock to consultants in consideration of various investor relations and business development services provided to the Company. The is

NXTS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning NXTS (Nexentis Technologies Inc.). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.

Recent NXTS coverage spans corporate actions, technology and financial news.

What's driving NXTS

AlphAI scores every news story that mentions NXTS with an AI model for sentiment and relevance, and aggregates insider trades from Nexentis Technologies Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NXTS

Score

Nexentis 3Q 2026: EPS ($0.29) — 10-Q Summary

Nexentis reported a net gain of $5.0 million, up from $429,000 a year earlier, driven by higher financing income. The company had no revenue from biotech or renewable energy projects. Financing income rose $6.9 million, while R&D expenses were $288,000. MitoCareX completed an initial screening stage under its Boltz initiative.

Nexentis Technologies Inc. (NXTS): Unregistered Sales of Equity Securities

Nexentis Technologies Inc. (NXTS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02. Unregistered Sales of Equity Securities. On November 9, 2026, Nexentis Technologies Inc. (the “Company”) issued 72,000 shares of common stock to consultants in consideration of various investor relations and business development services provided to the Company. The is

$NXTSMedStock split

Nexentis Announces Reverse Stock Split

Nexentis Technologies Inc. (NXTS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Nexentis Announces Reverse Stock Split Ness Ziona, Israel, November 5, 2026 (GLOBE NEWSWIRE) — Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build)

An AI drug search has its first predictions. They still need lab testing.

Nexentis Technologies Inc. (NASDAQ: NXTS) subsidiary MitoCareX Bio completed initial AI-driven drug-discovery screening with Boltz, PBC. Preliminary predictions are encouraging but require further validation. The initiative combines MitoCareX's drug-discovery capabilities with Boltz's AI models. No assurance is given that any identified compounds will advance to clinical development.

Nexentis Technologies Inc. (NXTS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Nexentis Technologies Inc. (NXTS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 3.02. Unregistered Sales of Equity Securities. On October 15, 2026, Nexentis Technologies Inc. (the “Company”) issued (i) 51,000 shares of common stock to a consultant for accounting and controller services provided to the Company; (ii) 101,549 shares of its common stock to

Nexentis subsidiary deploys drug discovery platform on Google Cloud

Nexentis Technologies (NXTS) announced its subsidiary MitoCareX Bio deployed its drug discovery platform on Google Cloud. The move aims to enhance computing capacity, data governance, and operational flexibility for drug discovery programs. Nexentis CEO David Palach called it a key step for MitoCareX's development. The company also invests in European renewable energy assets.

Related tickers